
ARM fosters investment, research & development, commercialization, and access to safe, effective, and transformational treatments and cures.
ARM fosters investment, research & development, commercialization, and access to safe, effective, and transformational treatments and cures.
Innovation in Released August 6, ARM’s H1 2020 Global Regenerative Medicine & Advanced Therapies Sector Report provides an in-depth look at trends and metrics in the gene, cell, and tissue-based therapeutic sector in the midst of the pandemic. The sector is poised for record-breaking financings in 2020, with several notable policy wins in the first half. Most importantly, patients are continuing to benefit from these transformative therapies.
This spring, ARM hosted experts on biotech fundraising, market access, value-based therapies, clinical trials amidst the pandemic, and cell therapies to treat COVID-19 as a part of a webinar series on timely sector issues.
Produced by the Marwood Institute and funded by ARM, this report uses a “Transformative Therapy Value Model,” and demonstrates that durable cell or gene therapies for multiple myeloma, sickle cell disease, and hemophilia A could provide cumulative cost-savings of $33B over the next ten years.
ARM CEO Janet Lambert discusses milestones from the cell and gene therapy sector over the past year and gives an update on the current financial, clinical, and policy environment for these innovative therapies.
Potentially curative cell and gene therapies are changing the face of medicine and providing hope to patients where there was once none. But how will they be paid for? This webinar discusses the implementation of value-based payment models for innovative therapies.
The webinar includes discussion around how COVID-19 changes the way we think about healthcare decision making and places intense pressure on financial management at all levels of the health system.
This webinar highlights potential treatments for Acute Respiratory Distress syndrome (ARDS) in COVID-19 patients. Two therapeutic developers, Athersys and Pluristem Therapeutics, presented on their treatment approaches and plans for near term clinical trials.
Janet Lambert, CEO, ARM
This presentation identifies major milestones in the gene therapy and cell therapy field over the past year and provides an overview of the financial, clinical, and policy environment.
Janet Lambert, CEO, ARM
The presentation, which provides an overview on value demonstration for cell and gene therapies, cites information from ARM’s library of original policy analyses.
Janet Lambert, CEO, ARM
The presentation, which provides an overview of public policy considerations for the cell and gene therapy sector, cites information from ARM’s library of original policy analyses.
Annie Hubert, Sr. Director, European Policy, ARM
This presentation draws on conclusions from ARM’s 2020 position paper on providing cross-border access to ATMPs in Europe, available here.
Michael Lehmicke, Director, Science & Industry Affairs, ARM
Additional information on ARM’s manufacturing initiatives is available here.
Robert Falb, Director, US Policy & Advocacy, ARM
The presentation provides an overview of the cell and gene therapy sector, with an emphasis on CAR-T therapies and related policy provisions.
Annie Hubert, Sr. Director, European Policy, ARM
This presentation provides an overview of the European ATMP sector, including financings, clinical development, and ARM’s European policy priorities.
Janet Lambert, CEO, ARM
This presentation, which includes data from ARM’s 2019 Global Sector Report, provides an overview of the regenerative medicine and advanced therapy sector for conference attendees.
Janet Lambert, CEO, ARM
ARM’s annual State of the Industry briefing provides an update on global financings, clinical development, public policy considerations, and other regenerative medicine sector trends. A recording of the presentation is available here.
Janet Lambert, CEO, ARM
This roundtable event brought together sector stakeholders to discuss improved patient access to ATMPs in Europe. The presentation included an overview of ARM’s Getting Ready report.
Janet Lambert, CEO, ARM & Michael Werner, Sr. Policy Counsel, ARM
ARM provided an overview of regulatory considerations in the US, Europe, and abroad for the International Coalition of Medicines Regulatory Authorities.
Annie Hubert, Sr. Director, European Policy, ARM
The presentation included an overview of the financial and clinical landscape for the development of gene therapies for rare disorders and policy priorities to promote development and patient access.
Janet Lambert, CEO, ARM
ARM provided an overview of the gene therapy sector for the New York Academy of Sciences, including the clinical landscape for innovative gene-editing technologies.
Janet Lambert, CEO, ARM
This presentation provides an overview of ARM to attendees at the annual Meeting on the Mesa. For more information on the Meeting on the Mesa, click here. A recording of the remarks is available here.
Janet Lambert, CEO, ARM
ARM CEO Janet Lambert annual Meeting on the Mesa. For more information on the Meeting on the Mesa, click here. A recording of the presentation is available here.